Clinical trials for Psoriasis AND Plaque Psoriasis

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44334 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (416)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

416 result(s) found for: Psoriasis AND Plaque Psoriasis. Displaying page 1 of 21.

EudraCT Number: 2013-000164-28

Sponsor Protocol Number: 8400-201

Start Date*: 2013-04-04

Sponsor Name:Idera Pharmaceuticals, Inc.

Full Title: A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis

Medical condition: Moderate to Severe Plaque Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10040785 - Skin and subcutaneous tissue disorders	10071117	Plaque psoriasis	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10050577	Psoriatic plaque	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: (No results available)

EudraCT Number: 2015-000943-17

Sponsor Protocol Number: NL54557.091.15

Start Date*: 2016-02-11

Sponsor Name:Radboudumc

Full Title: Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.

Medical condition: Adult Patients diagnosed psoriasis vulgaris

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10040785 - Skin and subcutaneous tissue disorders	10071117	Plaque psoriasis	LLT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10050576	Psoriasis vulgaris	LLT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10015581	Exacerbation of psoriasis	LLT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10037155	Psoriasis and similar disorders	LLT
	18.1	10040785 - Skin and subcutaneous tissue disorders	10037156	Psoriasis flare-up	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: View results

EudraCT Number: 2009-010863-18

Sponsor Protocol Number: NL26548.101.09

Start Date*: 2010-06-25

Sponsor Name:Amphia ziekenhuis

Full Title: The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial

Medical condition: Psoriasis patient getting UVB lighttherapy in a dermatological daycare center

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10015581	Exacerbation of psoriasis	LLT
	9.1		10037153	Psoriasis	LLT
	9.1		10050576	Psoriasis vulgaris	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-003287-37

Sponsor Protocol Number: EMR200588-002

Start Date*: 2016-03-15

Sponsor Name:Merck KGaA

Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro...

Medical condition: moderate to severe plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2014-000710-53

Sponsor Protocol Number: RD.06.SPR.18131

Start Date*: 2014-12-19

Sponsor Name:GALDERMA R&D, LLC

Full Title: A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months o...

Medical condition: Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: DE (Completed) IT (Completed) BE (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2008-005518-29

Sponsor Protocol Number: 08F/BET01

Start Date*: 2008-12-01

Sponsor Name:Laboratoires GENEVRIER

Full Title: An exploratory, open-label, intra-individual,active- controlled study comparing the efficacy and safety of Betesil versus Daivobet for the treatment of chronic plaque psoriasis

Medical condition: Chronic plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10037153	Psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-001568-12

Sponsor Protocol Number: 16-02/CalciBet-S

Start Date*: 2016-10-18

Sponsor Name:Dermapharm AG

Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...

Medical condition: chronic stable plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.1	10040785 - Skin and subcutaneous tissue disorders	10071117	Plaque psoriasis	LLT
	19.1	10040785 - Skin and subcutaneous tissue disorders	10050576	Psoriasis vulgaris	LLT
	19.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Completed)

Trial results: View results

EudraCT Number: 2014-003513-28

Sponsor Protocol Number: PS0005

Start Date*: 2015-03-27

Sponsor Name:UCB Biopharma, SPRL

Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects...

Medical condition: Plaque Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) CZ (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2011-002970-22

Sponsor Protocol Number: I1F-MC-RHAZ(c)

Start Date*: 2012-05-31

Sponsor Name:Eli Lilly and Company

Full Title: Protocol I1F-MC-RHAZ A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extensio...

Medical condition: Moderate to severe chronic plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) GB (Completed) HU (Completed) PL (Completed) IT (Completed) DK (Completed)

Trial results: View results

EudraCT Number: 2006-002738-39

Sponsor Protocol Number: 04-7-011

Start Date*: 2006-09-22

Sponsor Name:Astelleas Pharma US, Inc.

Full Title: A Phase 1 Open-Label Study of the Pharmacokinetics of Tacrolimus Cream B 0.1% after Twice Daily Topical Administration in Adolescents (≥ 12 to ≤ 17 Years of Age ) with Psoriasis

Medical condition: Determination of pharmacokinetics and safety of tacrolimus in adolescents with plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10037153	Psoriasis	LLT

Population Age: Adolescents, Under 18

Gender: Male, Female

Trial protocol: LV (Completed)

Trial results: View results

EudraCT Number: 2020-004061-39

Sponsor Protocol Number: CNTO1959PSO4015

Start Date*: 2021-10-22

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

Medical condition: Plaque Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) SE (Completed) GR (Prematurely Ended) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-004320-16

Sponsor Protocol Number: 77242113PSO2002

Start Date*: 2022-07-05

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Medical condition: Plaque Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Ongoing) PL (Completed)

Trial results: View results

EudraCT Number: 2011-000571-13

Sponsor Protocol Number: VIC-PSO1

Start Date*: 2011-05-24

Sponsor Name:Gentofte Hospital

Full Title: The effect of GLP-1 in psoriasis

Medical condition: Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: (No results available)

EudraCT Number: 2011-001066-17

Sponsor Protocol Number: CNTO1959PSO2001

Start Date*: 2012-04-10

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...

Medical condition: Moderate to Severe Plaque-type Psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2007-001630-14

Sponsor Protocol Number: DRN0307

Start Date*: 2007-10-30

Sponsor Name:University Medical Centre St. Radboud, Department of Dermatology

Full Title: Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.

Medical condition: Moderate to severe chronic plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10050576	Psoriasis vulgaris	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2012-002640-25

Sponsor Protocol Number: RR12/10234

Start Date*: 2013-02-07

Sponsor Name:University of Leeds/Leeds Teaching Hospitals NHS Trust

Full Title: A prospective, single-centre, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and ...

Medical condition: Psoriatic disease (psoriasis and psoriatic arthritis).

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	100000004859	10066579	Progression of psoriatic arthritis	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10071117	Plaque psoriasis	LLT
	14.1	100000004859	10037160	Psoriatic arthritis	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10050576	Psoriasis vulgaris	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10037153	Psoriasis	PT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10037157	Psoriasis of scalp	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10063407	Psoriasis genital	LLT
	14.1	10040785 - Skin and subcutaneous tissue disorders	10028703	Nail psoriasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2022-002887-59

Sponsor Protocol Number: VTX958-201

Start Date*: 2023-03-01

Sponsor Name:Ventyx Biosciences, Inc.

Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis

Medical condition: moderate to severe plaque psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10071117	Plaque psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2009-014364-18

Sponsor Protocol Number: 579/09

Start Date*: 2009-10-01

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE.

Medical condition: PSORIASIS

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.0		10037153	Psoriasis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2006-007011-24

Sponsor Protocol Number: 1583

Start Date*: 2007-09-21

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment

Medical condition: moderate to severe psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	6.1		10037153		PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2015-002628-14

Sponsor Protocol Number: I1F-MC-RHBQ

Start Date*: 2016-06-08

Sponsor Name: [...]

Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis

Medical condition: Moderate-to-severe genital psoriasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	100000004858	10063407	Psoriasis genital	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed) AT (Completed) BE (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Sat May 03 07:07:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA